Sharp Declines for uniQure, Fair Isaac, and ClearPoint Neuro in US Trading

Key Facts

1uniQure shares fell 37.33% following mixed four-year data for its Huntington’s disease gene therapy.

2Fair Isaac shares dropped 26.52% as US housing regulators moved to expand the use of rival VantageScore.

3ClearPoint Neuro shares declined 23.12% despite reporting 18% year-over-year revenue growth.

uniQure shares fell 37.33% following the release of mixed four-year data for its experimental Huntington’s disease gene therapy. Financial Modeling Prep reported that Fair Isaac Corporation shares dropped 26.52% as US housing regulators moved to expand the use of the rival VantageScore system, while ClearPoint Neuro declined 23.12% despite reporting 18% year-over-year revenue growth.

These instruments saw significant price adjustments from their previous levels; QURE closed at $39.11 on September 28, 2026, and FICO closed at $840.89 on the same date. In the neuro-technology sector, CLPT closed at $15.31 on September 28, 2026, while GrafTech International fell 14.16% amid broader headwinds in the steel industry after EAF closed at $9.96 on September 28, 2026.